Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

October 23, 2019

Cyclo Therapeutics completes enrollment in phase 1 trial to evaluate Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C

Cyclo Therapeutics, formerly CTD Holdings, a biotechnology company that develops cyclodextrin-based products for the treatment of disease, announced that it has completed patient enrollment in its Phase I trial to evaluate the safety and tolerability of Trappsol Cyclo administered intravenously to Niemann-Pick Disease Type C (NPC) patients.

Cyclo Therapeutics completes enrollment in phase 1 trial to evaluate Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C